Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome - 16/08/11
, Luigi Padeletti, MD b, Massimo Santini, MD c, Michele Gulizia, MD d, Serafino Orazi, MD e, GianLuca Botto, MD f, Alessandro Capucci, MD g, Mauro Biffi, MD a, Cristian Martignani, MD a, Renato Ricci, MD c, Marco Vimercati, MS h, Paola DiStefano, MS h, Andrea Grammatico, PhD hRésumé |
Background |
In sinus node disease (SND) atrial tachyarrhythmias (ATs) may frequently occur, after implant of a pacemaker for bradycardia, and are to be managed by rate or rhythm control.
Methods |
We evaluated ventricular heart rate (HR) during AT, AT-related symptoms and hospitalizations in 333 patients who received DDDRP pacemakers for SND.
Results |
In days with 24 hours of AT, mean daily HR during AT was >80, 90, 100, 110, and 120 beats per minute (bpm) in 191 (57%), 114 (34%), 55 (16%), 23 (7%), and 11 (3%) patients, respectively. The proportion of patients with a mean daily HR >80 bpm during AT despite the use of rate control agents was 28% among patients treated with calcium-channel blockers, 43% with digoxin, 49% with a combination of agents, 54% with amiodarone, 64% with sotalol, and 69% with β blockers. Patients with HR >100 bpm experienced a higher prevalence of both AT-related hospitalizations and cardiovascular hospitalizations than those with HR ≤100 bpm (36% vs 21%, P = .013; 42% vs 28%, P = .003) and a significantly higher number of AT-related symptoms (1.8 ± 0.9 vs 1.4 ± 1.0, P = .008).
Conclusions |
Limited attention has been dedicated to rate control in patients with pacemaker. This is the first study to evaluate the prevalence and implications of inappropriate rate control in patients with pacemaker. We found that in a substantial proportion of patients with SND who have recurrent ATs despite pacing, mean daily HR during AT is high and that these patients present increased hospitalizations and more symptoms, thus suggesting the need to improve rate control.
Le texte complet de cet article est disponible en PDF.Plan
| No financial support was given to the study. Marco Vimercati, Paola DiStefano, and Andrea Grammatico are employee of Medtronic Italy, affiliate of Medtronic Inc. the producer of the pacemaker used in this study. Other authors have no conflict of interest to state. |
Vol 154 - N° 1
P. 193-200 - juillet 2007 Retour au numéro
Article précédent
- Comparison of surgical and transcatheter treatment for native coarctation of the aorta in patients ?1 year old. The Quebec Native Coarctation of the Aorta Study
- Josep Rodés-Cabau, Joaquim Miró, Adrian Dancea, Reda Ibrahim, Eric Piette, Chantale Lapierre, Luc Jutras, Jean Perron, Christo I. Tchervenkow, Nancy Poirier, Nagib S. Dahdah, Christine Houde
- Letter to the Editor
- Sara Piciucchi, Carlo Cosimo Quattrocchi, Rosario Francesco Grasso, Bruno Beomonte Zobel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?